Inventor · disambiguated record
Wolfgang Schaefer
Also filed as: SCHAEFER WOLFGANG
52 granted patents·52 pending applications·765 citations·filing 1994–2025
98Inventor score
Top patents by PatentIndex Score
104 records- 0198US8242247B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2008·Granted Aug 14, 2012·110 cites·13 claims
- 0298US8227577B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2008·Granted Jul 24, 2012·148 cites·5 claims
- 0397US11673945B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2020·Granted Jun 13, 2023·4 cites·9 claims
- 0497US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0595US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0695US9266967B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2008·Granted Feb 23, 2016·30 cites·15 claims
- 0795US8703132B2Bispecific, tetravalent antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Apr 22, 2014·64 cites·11 claims
- 0894US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 0994US8945552B2Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2011·Granted Feb 3, 2015·36 cites·12 claims
- 1094US8796424B2Tri- or tetraspecific antibodiesCROASDALE REBECCA·Filed 2010·Granted Aug 5, 2014·59 cites·26 claims
- 1194US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 1292US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 1392US10633457B2Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2017·Granted Apr 28, 2020·6 cites·7 claims
- 1492US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 1592US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 1692US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 1791US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 1891US10611825B2Monovalent antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted Apr 7, 2020·6 cites·8 claims
- 1991US10323099B2Multispecific domain exchanged common variable light chain antibodiesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 18, 2019·13 cites·12 claims
- 2091US9982036B2Dual FC antigen binding proteinsBOSSENMAIER BIRGIT·Filed 2012·Granted May 29, 2018·12 cites·3 claims
- 2190US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 2290US11091541B2Human FcRn-binding modified antibodies and methods of useHOFFMANN LA ROCHE·Filed 2015·Granted Aug 17, 2021·6 cites·7 claims
- 2389US6531472B2Tetralone derivativesHOFFMANN LA ROCHE·Filed 2001·Granted Mar 11, 2003·23 cites·8 claims
- 2488US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 2587US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 2687US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2785US10138293B2Bivalent, bispecific antibodiesKLEIN CHRISTIAN·Filed 2012·Granted Nov 27, 2018·6 cites·12 claims
- 2885US8067599B2Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitorsHONOLD KONRAD·Filed 2007·Granted Nov 29, 2011·11 cites·9 claims
- 2985US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3084US10640555B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted May 5, 2020·2 cites·2 claims
- 3184US2023399391A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3284US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3383US12264196B2Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Apr 1, 2025·1 cites·14 claims
- 3483US10927163B2Bivalent, bispecific antibodiesHOFFMANN LA ROCHE·Filed 2018·Granted Feb 23, 2021·1 cites·26 claims
- 3583US7655651B2Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Feb 2, 2010·9 cites·8 claims
- 3683US7494993B2Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Feb 24, 2009·8 cites·15 claims
- 3783US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3882US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3982US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4081US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 4181US9676845B2Bispecific antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Jun 13, 2017·5 cites·8 claims
- 4278US10584178B2Bispecific HER2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 10, 2020·2 cites·6 claims
- 4378US2022324955A1Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4477US7786113B2Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Aug 31, 2010·3 cites·9 claims
- 4577US7618964B2Benzamide derivatives, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Nov 17, 2009·3 cites·11 claims
- 4675US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 4775US8058283B27H-pyrido[3,4-D]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitorsHONOLD KONRAD·Filed 2007·Granted Nov 15, 2011·4 cites·6 claims
- 4873US7550589B26-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitorsHOFFMANN LA ROCHE·Filed 2005·Granted Jun 23, 2009·1 cites·2 claims
- 4972US2021047394A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 5071US7189732B2Pyrido[2,3-d]pyrimidine dichloro-phenyl derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Mar 13, 2007·1 cites·16 claims
Showing the top 50 of 104 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Wolfgang Schaefer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →